IDG Capital joined a $44 million Series B financing round for Creative Biosciences, a Chinese producer of cancer screening and diagnostic kits. The Guangzhou-based company also recently released an early diagnosis kit for colon cancer which the National Medical Products Administration of China approved and licensed in 2018. Creative Biosciences said it is also developing early diagnosis products for lung cancer and bladder cancer tumors. Founded in 2015, Creative Biosciences nod has testing institutes in Guangzhou and Tianjin.

EdiGene, a Japanese biotechnology firm that develops genome-editing technologies for therapeutics to treat genetic diseases and cancer, has raised $14.4 million during its Series B round. EdiGene currently has operations in Guangzhou, China and Cambridge, Massachusetts. IDG Capital led EdiGene's Series A funding round in 2018 and also joined another $10 million financing round in 2019.